The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.
Related Articles
Study Identifies Homelessness as a Predictor Against Clozapine Use
A study identified homelessness and minority status as factors that impact clozapine prescription patterns.
FDA Approves Acoramidis (Attruby) for ATTR-CM
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
Trump picks former Rep. Dave Weldon to lead CDC
President-elect Donald Trump has selected Dave Weldon, a physician and former congressman, to lead the Centers for Disease Control and Prevention.
Why whooping cough cases are spiking across the U.S.
Whooping cough cases haven’t been this high at this time of year since 2014, according to the CDC
Trump picks Johns Hopkins surgeon Makary to run FDA
Makary is a close ally of Robert F. Kennedy Jr. and a proponent of his “Make America Healthy Again” movement to fight chronic diseases.
John Tesser, MD: Improving Outcomes in RA With Vagus Nerve Stimulation
Tesser discussed the background of the phase 3 RESET-RA trial and efficacy findings.
BridgeBio wins FDA approval for heart disease drug
The FDA approved a new medicine from BridgeBio for patients with ATTR-CM, a progressive heart disease
China Wiretaps Americans in ‘Worst Hack in Our Nation’s History’
America’s aging infrastructure seems to be the culprit.
Scientists grow human brains in space to treat Alzheimer’s
Scientists on the International Space Station (ISS) have grown brain-like organoids in space to research new treatments for Alzheimer’s, Parkinson’s and spinal injuries.
